Phaseline

Companies › Laekna

Laekna: clinical trials, targets and expected readouts

3 active drug programs in 4 registered trials: 3 Phase 1, 1 Phase 3; Metabolic and endocrine, Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Afuresertib
Serine/threonine-protein kinase AKT inhibitor
AKT2, AKT3, AKT1Phase 3Breast CancerDec 2026
LAE102–Phase 1Overweight and Obese Volunteers; Overweight and ObesityMar 2028
LAE103–Phase 1Overweight and ObesityMar 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06493084LAE102Phase 1Overweight and Obese VolunteersMetabolic and endocrineSep 2026
NCT04851613AfuresertibPhase 3Breast CancerOncologyDec 2026
NCT07230496LAE102Phase 1Overweight and ObesityMetabolic and endocrineMar 2028
NCT07230496LAE103Phase 1Overweight and ObesityMetabolic and endocrineMar 2028

Targets

AKT2 (1) AKT3 (1) AKT1 (1)

Companies with the same targets

AstraZeneca Merck & Co. (MSD) Roche Alterome Therapeutics Zhejiang Haichang Biotech Atavistik Bio

Companies built like this

JCR Pharmaceuticals Zhejiang Haichang Biotech Ascletis Pharma (China) The United Bio-Technology (Hengqin) BrightGene Bio-Medical Technology

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.